Benjamin F. Edwards & Company, Inc. Ligand Pharmaceuticals Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 790 shares of LGND stock, worth $88,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
790Holding current value
$88,132% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding LGND
# of Institutions
257Shares Held
18.2MCall Options Held
26.8KPut Options Held
9.3K-
Black Rock Inc. New York, NY2.87MShares$320 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$220 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$113 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3887KShares$99 Million0.1% of portfolio
-
State Street Corp Boston, MA707KShares$78.9 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.88B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...